Please login to the form below

Not currently logged in
Email:
Password:

Merck earmarks €35m for Italian biologics site development

Pharma firm plans new biotech production line at its Bari facility

Bari

Merck KgAa is set to invest €35m to expand its manufacturing site in the town of Modugno, Bari in Italy, to add a new production line for aseptic filing of biologics.

Expected to be fully operational by 2022, the new production line will support the growth of the company’s biotech medicines portfolio.

Stefan Oschmann, chairman of the executive board and CEO of Merck, said: “This investment underpins the importance of the Modugno-Bari production site for our growing healthcare business.”

Modugno is one of 15 manufacturing sites in operation by Merck and the facility currently employs around 225 people.

Oschmann added: “It will help us to secure the supply of medicines that improve people’s lives around the world.”

The new production line - which is expected to pump out 14 million units per year - will be used for biologic medicines for several disease areas including multiple sclerosis, fertility and endocrinology.

The move builds on a 2014 investment made by the pharma firm that saw it inject €50m into the site for a fully automated production line using isolator technology, as well as an automated warehouse.

Article by
Gemma Jones

10th October 2017

From: Research

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics